This document is an erratum for an article in the February 2011 issue of the Journal of Veterinary Emergency and Critical Care. It corrects errors in the third, fourth, and fifth paragraphs of the discussion section of the original article. The corrections clarify that the cats in the reported study were only treated with an oral formulation of mycophenolate mofetil, discuss the potential rapid onset of action of the drug, and note potential side effects seen in other species. The erratum concludes by restating that this is the first report of cats with primary immune-mediated hemolytic anemia being treated with glucocorticoid and mycophenolate mofetil therapy.

1. Erratum
Treatment of primary immune-mediated hemolytic
anemia with mycophenolate mofetil in two cats
Lenore M. Bacek, DVM and Douglass K. Macintire, DVM, MS, DACVIM, DACVECC
In the February 2011 issue (volume 21(1):45–49), on
page 48 of the article entitled ‘Treatment of primary
immune-mediated hemolytic anemia with mycopheno-
late mofetil in two cats’ by Drs. Bacek and Macintire,
there was an error in the discussion. The third, fourth
and fifth paragraphs should have read:
‘The cats described in this report were only treated
with an oral formulation of MMF, however, an IV
preparation of MMF also exists which would enable
clinicians to treat both the acute and chronic immune-
mediated disorders.11
Based on the experience of the
authors in managing the 2 cases reported here, MMF
may be useful as an adjunctive therapy in primary
IMHA in cats. Although the temporal relationship be-
tween initiation of therapy with MMF and cytological
evidence of disease remission is not known, a previous
pharmacokinetic study demonstrated maximal inhibi-
tion of IMPDH approximately 2–4 hours after oral ad-
ministration, suggesting a rapid onset of action.20
As the mechanism of action of MMF involves dis-
ruption of IMPDH-dependent purine synthesis, a wide
range of associated side effects is not surprising. The
most common adverse effects of MMF in people
include gastrointestinal signs, immunosuppression,
teratogenic effects, increased risk of lymphoma, hyper-
sensitivity reactions, headaches and neutropenia. These
side effects have been most commonly reported to oc-
cur between the 1st and 6th month after initiating ther-
apy.j
No studies have been performed in cats evaluating
adverse effects but the most common adverse effects
noted in dogs include weight loss, gastrointestinal up-
set, and mild allergic reactions during parenteral ad-
ministration.21,k
No adverse effects were noted in the
cases reported here.
As it is the case with other drugs, dosing cats can be
challenging and in the cases described in this report,
special compounding of MMF into 100 mg/mL sus-
pension was required. Normally, MMF is only available
as 250 and 500 mg capsules. To the authors’ knowledge,
this is the first report documenting the treatment of cats
with primary IMHA being treated with glucocorticoid
and MMF therapy. The dose of MMF used in the cats
described in this report was extrapolated from an oral
dose reported by Dewey et al22
(5–20 mg/kg, PO,
q12h) and has not been established for the treatment of
IMHA in cats.’
Journal of Veterinary Emergency and Critical Care 21(3) 2011, pp 285
doi:10.1111/j.1476-4431.2011.00642.x
& Veterinary Emergency and Critical Care Society 2011 285